Search JIM Advanced Search

Journal of Chinese Integrative Medicine ›› 2007, Vol. 5 ›› Issue (1): 85-91.doi: 10.3736/jcim20070118

• Literature Review • Previous Articles     Next Articles

Progress of treatment for bladder cancer

Zhi-cheng Cao   

  1. Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, ChinaAbstract
  • Online:2007-01-31 Published:2007-01-21

Key words: bladder neoplasms, integrated traditional and Western medicine, therapeutics, review

[1] Parkin DM, Bray F, Ferlay J , et al. Global cancer statistics, 2002[J]. CA Cancer J Clin, 2005,55(2):74-108
[2] Carreon T, LeMasters GK, Ruder AM , et al.The genetic and environmental factors involved in benzidine metabolism and bladder carcinogenesis in exposed workers[J].Front Biosci, 2006, 11 2889-2902
[3] Riedel K, Scherer G, Engl J , et al. Determination of three carcinogenic aromatic amines in urine of smokers and nonsmokers[J]. J Anal Toxicol, 2006,30(3):187-195
doi: 10.1109/96.544365 pmid: 16803653
[4] Samanic C, Kogevinas M, Dosemeci M , et al. Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender[J]. Cancer Epidemiol Biomarkers Prev, 2006,15(7):1348-1354
[5] Lin J, Spitz MR, Dinney CP , et al. Bladder cancer risk as modified by family history and smoking[J]. Cancer, 2006,107(4):705-711
doi: 10.1002/cncr.22071 pmid: 16845665
[6] Sidransky H . Tryptophan and carcinogenesis: review and update on how tryptophan may act[J]. Nutr Cancer, 1997,29(3):181-194
doi: 10.1080/01635589709514623 pmid: 9457738
[7] Badawi AF, Mostafa MH, Probert A , et al. Role of schistosomiasis in human bladder cancer: evidence of association, aetiological factors, and basic mechanisms of carcinogenesis[J]. Eur J Cancer Prev, 1995,4(1):45-59
[8] Pelucchi C, Bosetti C, Negri E , et al. Mechanisms of disease: The epidemiology of bladder cancer[J]. Nat Clin Pract Urol, 2006,3(6):327-340
doi: 10.1038/ncpuro0510 pmid: 16763645
[9] Kim WJ, Quan C . Genetic and epigenetic aspects of bladder cancer[J]. J Cell Biochem, 2005,95(1):24-33
doi: 10.1002/jcb.20412 pmid: 15759278
[10] Coogan CL, Estrada CR, Kapur S , et al. HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder[J]. Urology, 2004,63(4):786-790
doi: 10.1016/j.urology.2003.10.040
[11] Hirao S, Hirao T, Marsit CJ , et al. Loss of heterozygosity on chromosome 9q and p53 alterations in human bladder cancer[J]. Cancer, 2005,104(9):1918-1923
doi: 10.1002/cncr.21423 pmid: 16149093
[12] Tuziak T, Jeong J, Majewski T , et al. High-resolution whole-organ mapping with SNPs and its significance to early events of carcinogenesis[J]. Lab Invest, 2005,85(5):689-701
[13] Bernard-Pierrot I, Brams A, Dunois-Larde C , et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b[J]. Carcinogenesis, 2006,27(4):740-747
doi: 10.1093/carcin/bgi290 pmid: 16338952
[14] Lindgren D, Liedberg F, Andersson A , et al. Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q[J]. Oncogene, 2006,25(18):2685-2696
[15] Beecken WD, Engl T, Engels K , et al. Clinical relevance of maspin expression in bladder cancer[J]. World J Urol, 2006,24(3):338-344
doi: 10.1007/s00345-006-0085-z pmid: 16832651
[16] Ohlsson G, Moreira JM, Gromov P , et al. Loss of expression of the adipocyte-type fatty acid-binding protein(A-FABP) is associated with progression of human urothelial carcinomas[J]. Mol Cell Proteomics, 2005,4(4):570-581
[17] Brown FM . Urine cytology. It is still the gold standard for screening?[J]. Urol Clin North Am, 2000,27(1):25-37
doi: 10.1016/S0094-0143(05)70231-7 pmid: 10696242
[18] Bassi P, De Marco V, De Lisa A , et al. Non-invasive diagnostic tests for bladder cancer: a review of the literature[J]. Urol Int, 2005,75(3):193-200
[19] Drieskens O, Oyen R, Van Poppel H , et al. FDG-PET for preoperative staging of bladder cancer[J]. Eur J Nucl Med Mol Imaging, 2005,32(12):1412-1417
doi: 10.1007/s00259-005-1886-9 pmid: 16133380
[20] Picchio M, Treiber U, Beer AJ , et al. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings[J]. J Nucl Med, 2006,47(6):938-944
[21] Rodgers M, Nixon J, Hempel S , et al. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation[J].Health Technol Assess 2006, 10(18):iii-iv, xi-259
[22] Celis JE, Gromova I, Moreira JM , et al. Impact of proteomics on bladder cancer research[J]. Pharmacogenomics, 2004,5(4):381-394
doi: 10.1517/14622416.5.4.381 pmid: 15165174
[23] 曹志成, 余坚文, 梁荣能 . 蛋白质组学——引领后基因组时代[J]. 中国生物工程杂志, 2005,25(1):33-38
Cho CS, Yue KM , Leung WN.Proteomics--Leading the Postgenome Era[J].Zhongguo Sheng Wu Gong Cheng Za Zhi, 2005, 25(1):33-38. Chinese with abstract in English
[24] O'Riordan E , Goligorsky MS.Emerging studies of the urinary proteome: the end of the beginning?[J]. Curr Opin Nephrol Hypertens, 2005,14(6):579-585
[25] Konety BR . Molecular markers in bladder cancer: A critical appraisal[J]. Urol Oncol, 2006,24(4):326-337
doi: 10.1016/j.urolonc.2005.11.023 pmid: 16818187
[26] Liu BC, Ehrlich JR . Proteomics approaches to urologic diseases[J]. Expert Rev Proteomics, 2006,3(3):283-296
doi: 10.1586/14789450.3.3.283 pmid: 16771701
[27] Pisitkun T, Johnstone R, Knepper MA . Discovery of urinary biomarkers[J]. Mol Cell Proteomics, 2006,5(10):1760-1771
[28] Hoque MO, Begum S, Topaloglu O , et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection[J]. J Natl Cancer Inst, 2006,98(14):996-1004
doi: 10.1093/jnci/djj265 pmid: 16849682
[29] Osman I, Bajorin DF, Sun TT , et al. Novel blood biomarkers of human urinary bladder cancer[J]. Clin Cancer Res, 2006,12(11 Pt 1):3374-3380
doi: 10.1016/j.urolonc.2006.08.017 pmid: 16740760
[30] Feil G, Stenzl A . Tumor marker tests in bladder cancer[J]. Actas Urol Esp, 2006,30(1):38-45
doi: 10.4321/S0210-48062006000100006 pmid: 16703728
[31] Grossman HB, Messing E, Soloway M , et al. Detection of bladder cancer using a point-of-care proteomic assay[J]. JAMA, 2005,293(7):810-816
doi: 10.1001/jama.293.20.2467-a pmid: 15914744
[32] Svatek RS, Sagalowsky AI, Lotan Y . Economic impact of screening for bladder cancer using bladder tumor markers: A decision analysis[J]. Urol Oncol, 2006,24(4):338-343
[33] Akhtar M, Gallagher L, Rohan S . Survivin: role in diagnosis, prognosis, and treatment of bladder cancer[J]. Adv Anat Pathol, 2006,13(3):122-126
doi: 10.1097/00125480-200605000-00003 pmid: 16778475
[34] Sanchez-Carbayo M, Socci ND, Lozano JJ , et al. Profiling bladder cancer using targeted antibody arrays[J]. Am J Pathol, 2006,168(1):93-103
doi: 10.2353/ajpath.2006.050601 pmid: 16400012
[35] Stejskal D, Fiala RR . Evaluation of serum and urine clusterin as a potential tumor marker for urinary bladder cancer[J]. Neoplasma, 2006,53(4):343-346
pmid: 16830064
[36] Iwaki H, Kageyama S, Isono T , et al. Diagnostic potential in bladder cancer of a panel of tumor markers(calreticulin, gamma-synuclein, and catechol-o-methyltransferase) identified by proteomic analysis[J]. Cancer Sci, 2004,95(12):955-961
[37] Moreira JM, Gromov P, Celis JE . Expression of the tumor suppressor protein 14-3-3 sigma is down-regulated in invasive transitional cell carcinomas of the urinary bladder undergoing epithelial-to-mesenchymal transition[J]. Mol Cell Proteomics, 2004,3(4):410-419
[38] Vlahou A, Schellhammer PF, Mendrinos S , et al. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine[J]. Am J Pathol, 2001,158(4):1491-1502
[39] Lin CY, Tsui KH, Yu CC , et al. Searching cell-secreted proteomes for potential urinary bladder tumor markers[J]. Proteomics, 2006,6(15):4381-4389
doi: 10.1002/pmic.200600066 pmid: 16819731
[40] Wulfing C, Eltze E, Von Struensee D , et al. Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications[J]. Aktuelle Urol, 2004,35(4):331-338
doi: 10.1055/s-2004-818537 pmid: 15459875
[41] Fradet Y, Picard V, Bergeron A , et al. Cancer-testis antigen expression in bladder cancer[J]. Prog Urol, 2005,15(6 Suppl 1):1303-1313
doi: 10.1007/s00467-006-0193-4 pmid: 17069033
[42] Wulfing C, Eltze E, Piechota H , et al. Expression of endothelin-1 and endothelin-A and -B receptors in invasive bladder cancer[J]. Oncol Rep, 2005,13(2):223-228
[43] Xia G, Kumar SR, Hawes D , et al. Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer[J]. J Urol., 2006,175(4):1245-1252
doi: 10.1016/S0022-5347(05)00736-6 pmid: 16515971
[44] 曹志成 . 医疗新趋势——个体医疗[J].大众医学, 2004, 10 74-75
[45] Boccardo F , almeri L. Adjuvant chemotherapy of bladder cancer[J].Ann Oncol, 2006, 17 Suppl 5 v129-v132
doi: 10.1093/annonc/mdj967 pmid: 16807440
[46] Kaufman DS . Challenges in the treatment of bladder cancer[J]. Ann Oncol, 2006,17(Suppl 5):v106-v112
doi: 10.1093/annonc/mdj963 pmid: 16807436
[47] Oosterlinck W . Guidelines on diagnosis and treatment of superficial bladder cancer[J]. Minerva Urol Nefrol, 2004,56(1):65-72
pmid: 15195031
[48] Fokdal L , Hoyer M, von der Maase H . Radical radiotherapy for urinary bladder cancer: treatment outcomes[J]. Expert Rev Anticancer Ther, 2006,6(2):269-279
doi: 10.1586/14737140.6.2.269 pmid: 16445379
[49] Winquist E.Perioperative chemotherapy for localized bladder cancer[J].Can J Urol, 2006, 13 Suppl 1 77-80
[50] Garcia JA, Dreicer R . Adjuvant and neoadjuvant chemotherapy for bladder cancer: management and controversies[J]. Nat Clin Pract Urol, 2005,2(1):32-37
[51] Sternberg CN, Calabro F . Adjuvant chemotherapy for bladder cancer[J]. Expert Rev Anticancer Ther, 2005,5(6):987-992
[52] Mambrini A, Fiorentini G, Zamagni D , et al. Intra-arterial chemotherapy for invasive bladder cancer[J]. J Exp Clin Cancer Res, 2003,22(4 Suppl):21-23
doi: 10.1200/JCO.2003.10.925 pmid: 16767901
[53] Goebell PJ, Vom Dorp F, Rubben H . Value of systemic chemotherapy in bladder cancer[J]. Urologe A, 2006,45(5):586-593
doi: 10.1007/s00120-006-1058-y pmid: 16710678
[54] Bamias A, Dimopoulos MA . Neoadjuvant chemotherapy in invasive bladder cancer[J]. Expert Rev Anticancer Ther, 2005,5(6):993-1000
doi: 10.1038/bjc.1991.367 pmid: 1977623
[55] Roberts JT . Chemotherapy for metastatic bladder cancer[J]. Clin Oncol (R Coll Radiol), 2005,17(7):514-523
doi: 10.1016/j.clon.2005.07.007 pmid: 16238139
[56] Adorini L, Daniel KC, Penna G . Vitamin D receptor agonists, cancer and the immune system: an intricate relationship[J]. Curr Top Med Chem, 2006,6(12):1297-1301
doi: 10.2174/156802606777864890 pmid: 16848743
[57] Rosenberg JE, Carroll PR, Small EJ . Update on chemotherapy for advanced bladder cancer[J]. J Urol, 2005,174(1):14-20
doi: 10.1097/01.ju.0000162039.38023.5f pmid: 15947569
[58] Pagliaro LC, Sharma P . Review of metastatic bladder cancer[J]. Minerva Urol Nefrol, 2006,58(1):53-71
pmid: 16760884
[59] Roberts JT, von der Maase H, Sengelov L . et al. Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanc, 2006, 17 Suppl 5 v118-v122
[60] Siefker-Radtke A . Systemic chemotherapy options for metastatic bladder cancer[J]. Expert Rev Anticancer Ther, 2006,6(6):877-885
doi: 10.1586/14737140.6.6.877 pmid: 16761931
[61] Goebell PJ, Vom Dorp F, Rodel C , et al. Noninvasive and invasive bladder cancer: Diagnostics and treatment[J]. Urologe A, 2006,45(7):873-886
doi: 10.1007/s00120-006-1065-z pmid: 16791629
[62] Moskovitz B, Meyer G, Kravtzov A , et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients[J]. Ann Oncol, 2005,16(4):585-589
doi: 10.1093/annonc/mdi124 pmid: 15734775
[63] Muraro GB, Grifoni R , Spazzafumo L . Endoscopic therapy of superficial bladder cancer in high-risk patients: Holmium laser versus transurethral resection[J].Surg Technol Int, 2005,14 222-226
[64] Gwynn ES, Clark PE, Hall MC . Recent advances in the treatment of bladder cancer[J]. Expert Rev Anticancer Ther, 2005,5(6):1023-1030
doi: 10.1586/14737140.5.6.1023 pmid: 16336093
[65] 谢国材, 李捍东 . 常见肿瘤病防治(第1版)[M]. 广州: 广州出版社, 2003,( 第1版):107-110
Xie GC, Li HD. Prevention and treatment of common cancers(1st ed)[M]. Guangzhou: Guangzhou Press,2003,(1st ed):107-110. Chinese
[66] 陈世伟, 张利民 . 肿瘤中西医综合治疗(第1版)[M]. 北京: 人民卫生出版社, 2001,( 第1版):531-532
Chen SW, Zhang LM. Comprehensive treatment of tumor by traditional Chinese and Western medicine(1st ed)[M]. Beijing: People's Medical Publishing House,2001,(1st ed):531-532. Chinese
[67] 顾奎兴 . 中医肿瘤学(第1版)[M]. 南京: 东南大学出版社, 1998,( 第1版):127-129
Gu KX. Phymatology of traditional Chinese medicine(1st ed)[M]. Nanjing: Dongnan University Press,1998,(1st ed):127-129. Chinese
[68] 章永红 . 抗癌中药大全(第1版)[M]. 南京: 江苏科学技术出版社, 2000,( 第1版):34-425
Zhang YH. . Collection of anticancer traditional Chinese drugs(1st ed)[M]. Nanjing: Jiangsu Scientific and Technical Publishers,2000,(1st ed):34-425 2000,(1st ed):34-425. Chinese
[69] 吴玉生 . 常见肿瘤病中西医诊疗与调养(第1版)[M]. 广州: 广东旅游出版社, 2002,( 第1版):186-187
Wu YS. Diagnosis, treatment and nursing of common cancers by integrated traditional Chinese and Western medicine(1st ed)[M]. Guangzhou: Guangdong Tourism Press,2002,(1st ed):186-187. Chinese
[70] 周岱翰, 林丽珠 . 中医肿瘤食疗学(第1版)[M]. 贵阳: 贵州科学技术出版社, 2003,( 第1版):271-274
Zhou DH, Lin LZ.Phagotherapy of traditional Chinese medicine for tumor( 1st ed) [M].Guiyang: Guizhou Scientific and Technical Publishers , 2003,( 1st ed):271-274. Chinese
[71] 张代钊 . 中西医结合治疗放化疗毒副反应(第1版)[M]. 北京: 人民卫生出版社, 2000,( 第1版):283-308
Zhang DZ. Combined treatment of traditional Chinese and Western medicine for chemotherapeutic side reactions(1st ed)[M]. Beijing: People's Medical Publishing House,2000,(1st ed):283-308. Chinese
[72] 李岩, 王艳玲, 何其梅 . 肿瘤医护锦囊(第1版)[M]. 香港: 万里机构, 1997,( 第1版):203-204
Li Y, Wang YL, He QM.Collection of tumor treatments and nursing( 1st ed) [M].Hong Kong: Wanli Organization , 1997,( 1st ed):203-204. Chinese
[73] Adam L, Kassouf W , Dinney CP .Clinical applications for targeted therapy in bladder cancer [J].Urol Clin North Am, 2005, 32(2):239-246,vii
doi: 10.1016/j.ucl.2005.02.004 pmid: 15862621
[74] 曹志成 . 纳米医学[J]. 科学(上海), 2005,57(4):8-10
Cho CS.Nanomedicine[J].Ke Xue ( Shanghai), 2005, 57(4):8-10. Chinese
[75] Totterman TH, Loskog A, Essand M . The immunotherapy of prostate and bladder cancer[J]. BJU Int, 2005,96(5):728-735
doi: 10.1111/j.1464-410X.2005.05772.x pmid: 16144528
[76] Wang J, Liu XG, He CW , et al. Synergic anti-tumour effect of B7.1 gene modified tumour vaccine combined with allicin for murine bladder tumour[J]. Chin Med J (Engl), 2005,118(3):242-245
[77] Nagasawa J, Mizokami A, Koshida K , et al. Novel HER2 selective tyrosine kinase inhibitor, TAK-165, inhibits bladder, kidney and androgen-independent prostate cancer in vitro and in vivo[J]. Int J Urol, 2006,13(5):587-592
[78] Baselga J . Targeting tyrosine kinases in cancer: the second wave[J]. Science, 2006,312(5777):1175-1178
doi: 10.1126/science.1125951 pmid: 16728632
[79] Cho HJ, Kim JK, Kim KD , et al. Upregulation of Bcl-2 is associated with cisplatin-resistance via inhibition of Bax translocation in human bladder cancer cells[J]. Cancer Lett, 2006,237(1):56-66
[80] Fuessel S, Herrmann J, Ning S , et al. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA[J]. Cancer Lett, 2006,232(2):243-254
[81] Nogawa M, Yuasa T, Kimura S , et al. Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer[J]. J Clin Invest, 2005,115(4):978-985
[82] Ding Y, Wang G, Ling MT , et al. Significance of Id-1 up-regulation and its association with EGFR in bladder cancer cell invasion[J]. Int J Oncol, 2006,28(4):847-854
[83] Xia G, Kumar SR, Stein JP , et al. EphB4 receptor tyrosine kinase is expressed in bladder cancer and provides signals for cell survival[J]. Oncogene, 2006,25(5):769-780
[84] Zou L, Zhang P, Luo C , et al. shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity[J]. Cancer Chemother Pharmacol, 2006,57(3):328-334
[85] Horinaga M, Harsch KM, Fukuyama R , et al. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model[J]. Urology, 2005,66(2):461-466
doi: 10.1016/j.urology.2005.03.052 pmid: 16040105
[86] Mullerad M, Bochner BH, Adusumilli PS , et al. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma[J]. J Urol, 2005,174(2):741-746
[87] Terao S, Shirakawa T, Goda K , et al. Recombinant interleukin-2 enhanced the antitumor effect of ADV/RSV-HSV-tk/ACV therapy in a murine bladder cancer model[J]. Anticancer Res, 2005,25(4):2757-2760
[88] Inoue M, Tomizawa K, Matsushita M , et al. p53 protein transduction therapy: successful targeting and inhibition of the growth of the bladder cancer cells[J]. Eur Urol, 2006,49(1):161-168
doi: 10.1016/j.eururo.2005.08.019
[89] Lu Z, Yeh TK, Tsai M , et al. Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy[J]. Clin Cancer Res, 2004,10(22):7677-7684
doi: 10.1016/j.juro.2010.11.091 pmid: 15570001
[90] 曹志成 . 癌症病人的中医药治疗与调理[J]. 中华医药杂志, 2005,5(9):925-928
Cho CS. Treatment and rehabilitation for cancer patients with Chinese medicine[J].Zhonghua Yi Yao Za Zhi, 2005, 5(9):925-928.Chinese with abstract in English
[91] Mazzucchelli R, Barbisan F, Tarquini LM , et al. Urothelial changes induced by therapeutic procedures for bladder cancer. A review[J]. Anal Quant Cytol Histol, 2005,27(1):27-34
doi: 10.1016/j.amjsurg.2005.10.031 pmid: 15794449
[92] Alonzi R, Hoskin P . Novel therapies in bladder cancer[J]. Clin Oncol (R Coll Radiol), 2005,17(7):524-538
doi: 10.1016/j.clon.2005.07.001 pmid: 16238140
[93] So A, Rocchi P, Gleave M . Antisense oligonucleotide therapy in the management of bladder cancer[J]. Curr Opin Urol, 2005,15(5):320-327
doi: 10.1021/om00007a004 pmid: 16093856
[94] O'Kane HF , Watson CJ, Johnston SR, et al.Targeting death receptors in bladder, prostate and renal cancer[J]. J Urol, 2006,175(2):432-438
[95] Palena C, Abrams SI, Schlom J, et al.Cancer vaccines: preclinical studies and novel strategies[J].Adv Cancer Res , 2006, 95 115-145
[96] Pollera CF, Nelli F . Developing innovative strategies for advanced transitional cell carcinoma of the bladder[J]. Expert Rev Anticancer Ther, 2006,6(1):83-92
doi: 10.1586/14737140.6.1.83 pmid: 16375647
[97] Shah JB, Badalato GM , McKiernan JM.New treatments for superficial bladder cancer[J]. Curr Oncol Rep, 2006,8(3):201-205
doi: 10.1007/s11912-006-0020-x
[1] Dona Nirmani Ann Wijewickrama Samarakoon, Deepthi Inoka Uluwaduge, Malith Aravinda Siriwardhene. Mechanisms of action of Sri Lankan herbal medicines used in the treatment of diabetes: A review. Journal of Integrative Medicine, 2020, 18(1): 13-20.
[2] Lena Grönblom Lundström, Ulrika Aasa, Yan Zhang, Tobias Sundberg. Health care in light of different theories of health—A proposed framework for integrating a social humanistic perspective into health care. Journal of Integrative Medicine, 2019, 17(5): 321-327.
[3] Jia Xu, Fu-qing Zhang, Jian Pei, Jun Ji . Acupuncture for migraine without aura: A systematic review and meta-analysis. Journal of Integrative Medicine, 2018, 16(5): 312-321.
[4] Wen-jie Xu, Ling-tai Wang, Zhi-ping Zhao, Li-ming Zhu, Liang-hua Zu, Qi Zhang, Dan-bo Dou. Prospects of a comprehensive evaluation system for traditional Chinese medicine services. Journal of Integrative Medicine, 2017, 15(6): 426-432.
[5] Naseem Akhtar Qureshi, Gazzaffi Ibrahim Ali, Tamer Shaban Abushanab, Ahmed Tawfik El-Olemy, Meshari Saleh Alqaed, Ibrahim S. El-Subai, Abdullah M.N. Al-Bedah. History of cupping (Hijama): A narrative review of literature. Journal of Integrative Medicine, 2017, 15(3): 172-181.
[6] Tom Fleischer, Tung-Ti Chang, Hung-Rong Yen. Post-hematopoietic stem cell transplantation in patients with hematologic disorders: Chinese herbal medicine for an unmet need. Journal of Integrative Medicine, 2016, 14(5): 322-335.
[7] Eric Wei Chiang Chan, Siu Kuin Wong, Hung Tuck Chan. Apocynaceae species with antiproliferative and/or antiplasmodial properties: A review of ten genera. Journal of Integrative Medicine, 2016, 14(4): 269-284.
[8] JiaXia, Li-qunHe, XiaoSu. Interventional mechanisms of herbs or herbal extracts on renal interstitial fibrosis. Journal of Integrative Medicine, 2016, 14(3): 165-173.
[9] Yu-fangLin, Zhi-danLiu, WenMa, Wei-dongShen. Hazards of insomnia and the effects of acupuncture treatment on insomnia. Journal of Integrative Medicine, 2016, 14(3): 174-186.
[10] Jason Yamaki, Kalyan C. Nagulapalli Venkata, Animesh Mandal, Piyali Bhattacharyya, Anupam Bishayee. Health-promoting and disease-preventive potential of Trianthema portulacastrum Linn. (Gadabani)—An Indian medicinal and dietary plant. Journal of Integrative Medicine, 2016, 14(2): 84-99.
[11] Qing Ji, Yun-quan Luo, Wen-hai Wang, Xuan Liu, Qi Li, Shi-bing Su. Research advances in traditional Chinese medicine syndromes in cancer patients. Journal of Integrative Medicine, 2016, 14(1): 12-21.
[12] Wei Chiang Chan Eric, Kuin Wong Siu. Phytochemistry and pharmacology of ornamental gingers, Hedychium coronarium and Alpinia purpurata: A review. Journal of Integrative Medicine, 2015, 13(6): 368-379.
[13] Jessica Stanhope, Philip Weinstein, Angus Cook. Health effects of natural spring waters: A protocol for systematic reviews with a regional case example. Journal of Integrative Medicine, 2015, 13(6): 416-420.
[14] Xiao-ping Huang, Huang Ding, Jin-dong Lu, Ying-hong Tang, Bing-xiang Deng, Chang-qing Deng . Autophagy in cerebral ischemia and the effects of traditional Chinese medicine. Journal of Integrative Medicine, 2015, 13(5): 289-296.
[15] Amal Bakr Shori. Screening of antidiabetic and antioxidant activities of medicinal plants. Journal of Integrative Medicine, 2015, 13(5): 297-305.
Full text



[1] Jun Hu, Jian-ping Liu. Non-invasive physical treatments for chronic/recurrent headache. Journal of Chinese Integrative Medicine, 2008, 6(1): 31
[2] Yi-ting He, Qing-lin Zha, Jian-ping Yu, Yong Tan, Cheng Lu, Ai-ping Lv. Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine. Journal of Chinese Integrative Medicine, 2008, 6(1): 32-36
[3] Jun Cai, Hua Wang, Sheng Zhou, Bin Wu, Hua-rong Song, Zheng-rong Xuan. Effect of Sijunzi Decoction and enteral nutrition on T-cell subsets and nutritional status in patients with gastric cancer after operation: A randomized controlled trial. Journal of Chinese Integrative Medicine, 2008, 6(1): 37-40
[4] Dong Yang, Yong-ping Du, Qing Shen, Wei Chen, Yan Yu, Guang-lei Chen. Expression of alpha-smooth muscle actin in renal tubulointerstitium in patients with kidney collateral stasis. Journal of Chinese Integrative Medicine, 2008, 6(1): 41-44
[5] Xue-mei Liu, Qi-fu Huang, Yun-ling Zhang, Jin-li Lou, Hong-sheng Liu, Hong Zheng. Effects of Tribulus terrestris L. saponion on apoptosis of cortical neurons induced by hypoxia-reoxygenation in rats. Journal of Chinese Integrative Medicine, 2008, 6(1): 45-50
[6] SUN Ming-yu, ZUO Jian, DUAN Ji-feng, HAN Jun, FAN Shi-ming, ZHANG Wei, ZHU Li-fang, YAO Ming-hui. Antitumor activities of kushen flavonoids in vivo and in vitro. Journal of Chinese Integrative Medicine, 2008, 6(1): 51-59
[7] Xi Lin, Jian-ping Liu. Tai chi for treating rheumatoid arthritis. Journal of Chinese Integrative Medicine, 2008, 6(1): 82
[8] Guo-hong Yuan, Xiao-jing Pang, He-chao Ma. Synergic effects of Danggui Buxue Decoction in reducing toxicity of cytoxan in tumor-bearing mice. Journal of Chinese Integrative Medicine, 2008, 6(1): 83-88
[9] Jin-zhou Tian, Jing Shi, Xin-qing Zhang, Qi Bi, Xin Ma, Zhi-liang Wang, Xiao-bin Li, Shu-li Shen, Lin Li, Zhen-yun Wu, Li-yan Fang, Xiao-dong Zhao, Ying-chun Miao, Peng-wen Wang, Ying Ren, Jun-xiang Yin, Yong-yan Wang, Beijing United Study Group on MCI of the Capital Foundation of Medical Developments. Guiding principles of clinical research on mild cognitive impairment (protocol). Journal of Chinese Integrative Medicine, 2008, 6(1): 9-14
[10] Ning-qun Wang, Liang-duo Jiang, Zong-xing Li. Research progress in asthma-related quality of life. Journal of Chinese Integrative Medicine, 2008, 6(1): 93-97